Eye Disorders Are Focus Of Novel Neurostimulation Technologies
Neurostimulation technology is migrating into the ophthalmology field, and the implications could be significant for the millions of patients worldwide with degenerative eye diseases, including retinitis pigmentosa and age-related macular degeneration, as well as those with moderate-to-severe dry eye disease. Companies active in this space include Second Sight Medical Products, Retina Implant AG, Pixium Vision, Nano Retina, and many others.
You may also be interested in...
CMS met this week, and will again on June 3, to hear arguments in support of establishing new or revised level II HCPCS codes for 33 different durable medical equipment, prosthetics and orthotics items and medical supplies. But in preliminary rulings the agency signaled plans to deny all but two of the requests.
At its October Medical Innovation Summit, the Cleveland Clinic unveiled six device and diagnostics products that were selected for inclusion in its list of top 10 innovations for 2014.
Cook Medical’s Zilver PTX stent and Second Sight Medical Products’ Argus II retinal prosthesis system will enjoy new-technology add-on payments in 2014 under CMS’ hospital inpatient prospective payment system final rule.